Evaluation of Sitagliptin for the treatment of adult patients with type 2 diabetes mellitus: a systematic review of cost-effectiveness
Introduction: Type 2 diabetes mellitus is a global public health problem, being one of the main causes of mortality in Ecuador. Sitagliptin was the first locally marketed incretin-enhancing drug. Countries do not have unlimited resources to meet the health needs of their population, so they must ado...
সংরক্ষণ করুন:
| প্রধান লেখক: | |
|---|---|
| অন্যান্য লেখক: | , , |
| বিন্যাস: | article |
| ভাষা: | spa |
| প্রকাশিত: |
2020
|
| বিষয়গুলি: | |
| অনলাইন ব্যবহার করুন: | https://revistadigital.uce.edu.ec/index.php/CIENCIAS_MEDICAS/article/view/2661 |
| ট্যাগগুলো: |
ট্যাগ যুক্ত করুন
কোনো ট্যাগ নেই, প্রথমজন হিসাবে ট্যাগ করুন!
|
ট্যাগ যুক্ত করুন | _version_ | 1863544722050514944 |
|---|---|
| author | Rojas Velasco, Giovanni |
| author2 | Solís, Paola Gaona, Richard Nunes, Altacílio |
| author2_role | author author author |
| author_facet | Rojas Velasco, Giovanni Solís, Paola Gaona, Richard Nunes, Altacílio |
| author_role | author |
| collection | Revista Ciencias Médicas |
| dc.creator.none.fl_str_mv | Rojas Velasco, Giovanni Solís, Paola Gaona, Richard Nunes, Altacílio |
| dc.date.none.fl_str_mv | 2020-12-31 |
| dc.format.none.fl_str_mv | application/pdf |
| dc.identifier.none.fl_str_mv | https://revistadigital.uce.edu.ec/index.php/CIENCIAS_MEDICAS/article/view/2661 10.29166/rfcmq.v45i2.2661 |
| dc.language.none.fl_str_mv | spa |
| dc.publisher.none.fl_str_mv | Quito: Universidad Central del Ecuador |
| dc.relation.none.fl_str_mv | https://revistadigital.uce.edu.ec/index.php/CIENCIAS_MEDICAS/article/view/2661/5304 |
| dc.rights.none.fl_str_mv | Derechos de autor 2020 Giovanni Rojas Velasco, Paola Solís, Richard Gaona, Altacílio Nunes http://creativecommons.org/licenses/by-nc-nd/4.0 info:eu-repo/semantics/openAccess |
| dc.source.none.fl_str_mv | Revista de la Facultad de Ciencias Médicas (Quito); Vol. 45 No. 2 (2020): Revista de la Facultad de Ciencias Médicas (Quito); 8 - 20 Revista de la Facultad de Ciencias Médicas (Quito); Vol. 45 Núm. 2 (2020): Revista de la Facultad de Ciencias Médicas (Quito); 8 - 20 2737-6141 2588-0691 reponame:Revista Ciencias Médicas instname:Universidad Central del Ecuador instacron:UCE |
| dc.subject.none.fl_str_mv | sitagliptina diabetes mellitus costo-efectividad Diabetes Mellitus Tipo 2 evaluación económica sitagliptin diabetes mellitus cost-effectiveness Diabetes Mellitus, Type 2 Economic Evaluation |
| dc.title.none.fl_str_mv | Evaluation of Sitagliptin for the treatment of adult patients with type 2 diabetes mellitus: a systematic review of cost-effectiveness Evaluación de Sitagliptina para el tratamiento de pacientes adultos con diabetes mellitus tipo 2: revisión sistemática de costo-efectividad |
| dc.type.none.fl_str_mv | info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion Artículo evaluado por pares |
| description | Introduction: Type 2 diabetes mellitus is a global public health problem, being one of the main causes of mortality in Ecuador. Sitagliptin was the first locally marketed incretin-enhancing drug. Countries do not have unlimited resources to meet the health needs of their population, so they must adopt the most appropriate health interventions, considering the costs that a country can assume and sustain. Objective: To synthesize the results of cost-effectiveness studies of sitagliptin for combined oral treatment of adult patients with type 2 diabetes, compared with sulfonylureas. Methodology: This is a systematic review study without meta-analysis, conducted on PRISMA recommendations. The information search was structured under the PICO system. The searches were conducted in Pubmed, Tripdatabase and Pubmed Central; for articles on health technology evaluations, economic evaluations and clinical practice guides. For coverage policies, HTAiVortal and advanced Google were used. Results: 3 clinical trials and 8 systematic reviews-meta-analysis, 2 cohort studies, 3 coverage policies and 1 cost-effectiveness study were selected. Three systematic reviews establish modest effects regarding the hypoglycemic effects of sitagliptin in adults and elderly, with a low risk of hypoglycemia. A meta-analysis of 25 clinical trials reported an increased cardiovascular risk in patients treated with sitagliptin. A systematic review with economic evaluation showed that sitagliptin with metformin was a cost-effective alternative, versus adding a sulfonylurea or roziglitazone. Conclusions: Due to its cost-effectiveness profile, sitagliptin could be considered as a second drug for patients who do not achieve glycemic control with maximum doses of metformin, or where its association with a sulfonylurea is not feasible (due to risks of hypoglycemia or elderly). |
| eu_rights_str_mv | openAccess |
| format | article |
| id | REVCMED_941304e02ce3d1e287e4dbb82cf270ac |
| identifier_str_mv | 10.29166/rfcmq.v45i2.2661 |
| instacron_str | UCE |
| institution | UCE |
| instname_str | Universidad Central del Ecuador |
| language | spa |
| network_acronym_str | REVCMED |
| network_name_str | Revista Ciencias Médicas |
| oai_identifier_str | oai:revistadigital.uce.edu.ec:article/2661 |
| publishDate | 2020 |
| publisher.none.fl_str_mv | Quito: Universidad Central del Ecuador |
| reponame_str | Revista Ciencias Médicas |
| repository.mail.fl_str_mv | * |
| repository.name.fl_str_mv | Revista Ciencias Médicas - Universidad Central del Ecuador |
| repository_id_str | * |
| rights_invalid_str_mv | Derechos de autor 2020 Giovanni Rojas Velasco, Paola Solís, Richard Gaona, Altacílio Nunes http://creativecommons.org/licenses/by-nc-nd/4.0 |
| spelling | Evaluation of Sitagliptin for the treatment of adult patients with type 2 diabetes mellitus: a systematic review of cost-effectivenessEvaluación de Sitagliptina para el tratamiento de pacientes adultos con diabetes mellitus tipo 2: revisión sistemática de costo-efectividadRojas Velasco, GiovanniSolís, Paola Gaona, RichardNunes, Altacíliositagliptinadiabetes mellituscosto-efectividadDiabetes Mellitus Tipo 2evaluación económicasitagliptindiabetes mellituscost-effectivenessDiabetes Mellitus, Type 2Economic EvaluationIntroduction: Type 2 diabetes mellitus is a global public health problem, being one of the main causes of mortality in Ecuador. Sitagliptin was the first locally marketed incretin-enhancing drug. Countries do not have unlimited resources to meet the health needs of their population, so they must adopt the most appropriate health interventions, considering the costs that a country can assume and sustain. Objective: To synthesize the results of cost-effectiveness studies of sitagliptin for combined oral treatment of adult patients with type 2 diabetes, compared with sulfonylureas. Methodology: This is a systematic review study without meta-analysis, conducted on PRISMA recommendations. The information search was structured under the PICO system. The searches were conducted in Pubmed, Tripdatabase and Pubmed Central; for articles on health technology evaluations, economic evaluations and clinical practice guides. For coverage policies, HTAiVortal and advanced Google were used. Results: 3 clinical trials and 8 systematic reviews-meta-analysis, 2 cohort studies, 3 coverage policies and 1 cost-effectiveness study were selected. Three systematic reviews establish modest effects regarding the hypoglycemic effects of sitagliptin in adults and elderly, with a low risk of hypoglycemia. A meta-analysis of 25 clinical trials reported an increased cardiovascular risk in patients treated with sitagliptin. A systematic review with economic evaluation showed that sitagliptin with metformin was a cost-effective alternative, versus adding a sulfonylurea or roziglitazone. Conclusions: Due to its cost-effectiveness profile, sitagliptin could be considered as a second drug for patients who do not achieve glycemic control with maximum doses of metformin, or where its association with a sulfonylurea is not feasible (due to risks of hypoglycemia or elderly).Introducción: La diabetes mellitus tipo 2 es un problema de salud pública mundial, siendo de las principales causas de mortalidad en Ecuador. Sitagliptina fue el primer fármaco potenciador del sistema de las incretinas comercializado localmenteLos países no tienen recursos ilimitados para atender las necesidades de salud de su población, por lo que deben adoptar las intervenciones sanitarias más adecuadas, considerando los costos que un país pueda asumir y sostener. Objetivo: Sintetizar los resultados de estudios de costo-efectividad de la sitagliptina para el tratamiento oral combinado de pacientes adultos con diabetes tipo 2, en comparación con sulfonilureas. Metodología: Se trata de un estudio de revisión sistemática sin metaanálisis, realizado sobre las recomendaciones PRISMA. La búsqueda de información se estructuró bajo el sistema PICO. Las búsquedas se realizaron en Pubmed, Tripdatabase y Pubmed Central; para artículos de evaluaciones de tecnologías sanitarias, evaluaciones económicas y guías de práctica clínica. Para las políticas de cobertura se utilizó HTAiVortal y Google avanzado. Resultados: Se seleccionaron 3 ensayos clínicos y 8 revisiones sistemáticas-metaanálisis, 2 estudios de cohorte, 3 políticas de cobertura . Tres revisiones sistemáticas establecen efectos modestos en cuanto a los efectos hipoglicemiantes de sitagliptina en adultos y adultos mayores; con un bajo riesgo de hipoglicemia. Un metaanálisis de 25 ensayos clínicos reportó mayor riesgo cardiovascular en los pacientes tratados con sitagliptina. Una revisión sistemática con evaluación económica mostró que sitagliptina con metformina fue una alternativa costo-efectiva versus añadir una sulfonilurea o roziglitazona. Conclusiones: Por el perfil de costo-efectividad podría considerarse a sitagliptina como segundo fármaco para pacientes que no consiguen control glicémico con dosis máximas de metformina, o en donde su asociación a una sulfonilurea no sea factible (por riesgos de hipoglicemia o adultos mayores). Quito: Universidad Central del Ecuador2020-12-31info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionArtículo evaluado por paresapplication/pdfhttps://revistadigital.uce.edu.ec/index.php/CIENCIAS_MEDICAS/article/view/266110.29166/rfcmq.v45i2.2661Revista de la Facultad de Ciencias Médicas (Quito); Vol. 45 No. 2 (2020): Revista de la Facultad de Ciencias Médicas (Quito); 8 - 20Revista de la Facultad de Ciencias Médicas (Quito); Vol. 45 Núm. 2 (2020): Revista de la Facultad de Ciencias Médicas (Quito); 8 - 202737-61412588-0691reponame:Revista Ciencias Médicasinstname:Universidad Central del Ecuadorinstacron:UCEspahttps://revistadigital.uce.edu.ec/index.php/CIENCIAS_MEDICAS/article/view/2661/5304Derechos de autor 2020 Giovanni Rojas Velasco, Paola Solís, Richard Gaona, Altacílio Nuneshttp://creativecommons.org/licenses/by-nc-nd/4.0info:eu-repo/semantics/openAccess2023-09-11T17:34:22Zoai:revistadigital.uce.edu.ec:article/2661Portal de revistashttps://revistadigital.uce.edu.ec/Universidad públicahttps://uce.edu.ec/**Ecuador*2737-61412588-0691opendoar:*2023-09-11T17:34:22Revista Ciencias Médicas - Universidad Central del Ecuadorfalse |
| spellingShingle | Evaluation of Sitagliptin for the treatment of adult patients with type 2 diabetes mellitus: a systematic review of cost-effectiveness Rojas Velasco, Giovanni sitagliptina diabetes mellitus costo-efectividad Diabetes Mellitus Tipo 2 evaluación económica sitagliptin diabetes mellitus cost-effectiveness Diabetes Mellitus, Type 2 Economic Evaluation |
| status_str | publishedVersion |
| title | Evaluation of Sitagliptin for the treatment of adult patients with type 2 diabetes mellitus: a systematic review of cost-effectiveness |
| title_full | Evaluation of Sitagliptin for the treatment of adult patients with type 2 diabetes mellitus: a systematic review of cost-effectiveness |
| title_fullStr | Evaluation of Sitagliptin for the treatment of adult patients with type 2 diabetes mellitus: a systematic review of cost-effectiveness |
| title_full_unstemmed | Evaluation of Sitagliptin for the treatment of adult patients with type 2 diabetes mellitus: a systematic review of cost-effectiveness |
| title_short | Evaluation of Sitagliptin for the treatment of adult patients with type 2 diabetes mellitus: a systematic review of cost-effectiveness |
| title_sort | Evaluation of Sitagliptin for the treatment of adult patients with type 2 diabetes mellitus: a systematic review of cost-effectiveness |
| topic | sitagliptina diabetes mellitus costo-efectividad Diabetes Mellitus Tipo 2 evaluación económica sitagliptin diabetes mellitus cost-effectiveness Diabetes Mellitus, Type 2 Economic Evaluation |
| url | https://revistadigital.uce.edu.ec/index.php/CIENCIAS_MEDICAS/article/view/2661 |